NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Contributed by: GlobeNewswire

Tags

Healthcare

More Like This

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update